Tags

Type your tag names separated by a space and hit enter

Impact of pneumococcal vaccination in Denmark during the first 3 years after PCV introduction in the childhood immunization programme.
Vaccine. 2012 Jun 06; 30(26):3944-50.V

Abstract

BACKGROUND AND AIMS

The 7-valent pneumococcal conjugate vaccine (PCV7) was introduced in Denmark in October 2007 in a 2+1 schedule with a catch-up programme for children up to 17 months of age. To assess the impact of PCV we evaluated on the whole population: (1) direct and indirect effects on incidence of invasive pneumococcal disease (IPD), (2) changes in pneumococcal serotype distribution and (3) IPD related mortality.

METHODS

We compared disease incidence in pre-PCV (years 2000-2007) and PCV periods (years 2008-2010) based on national surveillance data.

RESULTS

In children aged 0-5 years the overall incidence of IPD decreased from 26.7 to 16.3 cases per 100,000 (IRR 0.58; 95% Confidence Interval (CI) [0.48-0.69]) and case fatality declined from 1.8% (12 deaths) in the eight-year pre-PCV period to 0% (no deaths) in the three-year PCV period. In the whole population the overall incidence of IPD and of IPD caused by vaccine serotypes declined significantly from 19.5 to 17.7 and from 7.7 to 3.8 cases per 100,000 persons comparing the two periods. The incidence of IPD due to non-vaccine serotypes (NVT-IPD) increased significantly from 11.8 to 13.9 cases per 100,000 in the whole population (incidence rate ratio 1.18; 95% CI [1.12-1.24]) with predominance of the serotypes 1.7F and 19A.

CONCLUSIONS

We report a marked decline in incidence in IPD in both vaccinated and non-vaccinated age groups and a minor but statistically significant increase in incidence of IPD due to NVTs in both vaccinated and non-vaccinated groups with predominance of serotypes covered by higher valence pneumococcal conjugate vaccines.

Authors+Show Affiliations

Neisseria and Streptococcus Reference Laboratory, Department of Microbiological Surveillance and Research, Statens Serum Institut (SSI), Copenhagen, Denmark. HIG@ssi.dk, helene ingels@yahoo.dkNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

22504662

Citation

Ingels, Helene, et al. "Impact of Pneumococcal Vaccination in Denmark During the First 3 Years After PCV Introduction in the Childhood Immunization Programme." Vaccine, vol. 30, no. 26, 2012, pp. 3944-50.
Ingels H, Rasmussen J, Andersen PH, et al. Impact of pneumococcal vaccination in Denmark during the first 3 years after PCV introduction in the childhood immunization programme. Vaccine. 2012;30(26):3944-50.
Ingels, H., Rasmussen, J., Andersen, P. H., Harboe, Z. B., Glismann, S., Konradsen, H., Hoffmann, S., Valentiner-Branth, P., & Lambertsen, L. (2012). Impact of pneumococcal vaccination in Denmark during the first 3 years after PCV introduction in the childhood immunization programme. Vaccine, 30(26), 3944-50. https://doi.org/10.1016/j.vaccine.2012.03.060
Ingels H, et al. Impact of Pneumococcal Vaccination in Denmark During the First 3 Years After PCV Introduction in the Childhood Immunization Programme. Vaccine. 2012 Jun 6;30(26):3944-50. PubMed PMID: 22504662.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Impact of pneumococcal vaccination in Denmark during the first 3 years after PCV introduction in the childhood immunization programme. AU - Ingels,Helene, AU - Rasmussen,Jeppe, AU - Andersen,Peter Henrik, AU - Harboe,Zitta B, AU - Glismann,Steffen, AU - Konradsen,Helle, AU - Hoffmann,Steen, AU - Valentiner-Branth,Palle, AU - Lambertsen,Lotte, AU - ,, Y1 - 2012/04/11/ PY - 2011/12/09/received PY - 2012/03/12/revised PY - 2012/03/20/accepted PY - 2012/4/17/entrez PY - 2012/4/17/pubmed PY - 2012/9/13/medline SP - 3944 EP - 50 JF - Vaccine JO - Vaccine VL - 30 IS - 26 N2 - BACKGROUND AND AIMS: The 7-valent pneumococcal conjugate vaccine (PCV7) was introduced in Denmark in October 2007 in a 2+1 schedule with a catch-up programme for children up to 17 months of age. To assess the impact of PCV we evaluated on the whole population: (1) direct and indirect effects on incidence of invasive pneumococcal disease (IPD), (2) changes in pneumococcal serotype distribution and (3) IPD related mortality. METHODS: We compared disease incidence in pre-PCV (years 2000-2007) and PCV periods (years 2008-2010) based on national surveillance data. RESULTS: In children aged 0-5 years the overall incidence of IPD decreased from 26.7 to 16.3 cases per 100,000 (IRR 0.58; 95% Confidence Interval (CI) [0.48-0.69]) and case fatality declined from 1.8% (12 deaths) in the eight-year pre-PCV period to 0% (no deaths) in the three-year PCV period. In the whole population the overall incidence of IPD and of IPD caused by vaccine serotypes declined significantly from 19.5 to 17.7 and from 7.7 to 3.8 cases per 100,000 persons comparing the two periods. The incidence of IPD due to non-vaccine serotypes (NVT-IPD) increased significantly from 11.8 to 13.9 cases per 100,000 in the whole population (incidence rate ratio 1.18; 95% CI [1.12-1.24]) with predominance of the serotypes 1.7F and 19A. CONCLUSIONS: We report a marked decline in incidence in IPD in both vaccinated and non-vaccinated age groups and a minor but statistically significant increase in incidence of IPD due to NVTs in both vaccinated and non-vaccinated groups with predominance of serotypes covered by higher valence pneumococcal conjugate vaccines. SN - 1873-2518 UR - https://www.unboundmedicine.com/medline/citation/22504662/Impact_of_pneumococcal_vaccination_in_Denmark_during_the_first_3_years_after_PCV_introduction_in_the_childhood_immunization_programme_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0264-410X(12)00452-5 DB - PRIME DP - Unbound Medicine ER -